PULMONARY

EXPERT VIEW

CAPSULES: CLASSIC DRUG DELIVERY FORM HOLDS POTENTIAL FOR SUSTAINABLE DELIVERY

Jnanadeva Bhat and Anita Solanki discuss the role that hard capsules are able to play in delivering a more sustainable pharmaceutical industry, both as an oral solid dosage form and in dry powder inhalers.

EXPERT VIEW

WAITING WITH BATED BREATH – WHAT’S IN STORE FOR 2022

Rob Udale and Heather Jameson discuss the exciting developments taking place in the design of inhalation devices and share their predictions for the top five inhalation trends to watch as 2022 unfolds, and beyond.

EXPERT VIEW

Rob Udale

ARE GOVERNMENTS BANNING THE MOST ENVIRONMENTALLY FRIENDLY INHALER?

Rob Udale, Catriona Eldridge and Omar Shah assess the assertion that pMDIs are the most environmentally damaging of the available pulmonary drug delivery device archetypes, and explore some of the intricacies not accounted for in the public discourse surrounding pMDIs.

SUSTAINABILITY

Rob Doorakkers

IGS GeboJagema

SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT

Rob Doorakkers and Geert van Amstel discuss why the company decided to become carbon neutral, how it is working to make injection moulding more sustainable and how the organisation is minimising its impact on the environment.

SUSTAINABILITY

Dr Pierre Moulinie

Covestro LLC

DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS

Pierre Moulinié, Isaac Platte and Lauren Zetts discuss how polycarbonate-based materials deliver value to emerging drug delivery devices.

SUSTAINABILITY

Nick Atkinson

Recipharm

HOW CAN THE PHARMA INDUSTRY PREPARE FOR NEW pMDI PROPELLANTS?

Nick Atkinson looks at the changes that are set to hit pressurised metered dose inhaler manufacturing as new propellants are introduced and how pharma companies can prepare for the switch.

SUSTAINABILITY

Chris Baron

Aptar Pharma

INVESTIGATING THE PROPELLANT PATHWAYS LEADING TO A SUSTAINABLE FUTURE FOR MDIS

Chris Baron and Jag Shur discuss the various dynamics involved in realising the full potential of MDIs to deliver both improved environmental performance and even better patient outcomes.

EXPERT VIEW

Frédérique Bordes-Picard

NANOTECHNOLOGY: A NEXT-GENERATION TOOL FOR PULMONARY & NASAL DELIVERY

Frédérique Bordes-Picard looks at the role of nanotechnology in the nasal and pulmonary routes of drug delivery and explains how nanoparticle explains how nanoparticle solutions could transform patient comfort and compliance.

EARLY INSIGHT

Dr Jason Brenker

Monash University

PERSONALISED AEROSOL LOADING AND MANAGEMENT (PALM): A HAND-HELD DEVICE FOR AEROSOL DRUG DELIVERY

Jason Brenker, Tuncay Alan and Daniela Traini introduce the PALM – Personalised Aerosol Loading and Management – device, a unique, advanced drug delivery device enabling personalised delivery of aerosols to improve the efficacy of inhaled medications and patient compliance.

EXPERT VIEW

Wilbur de Kruijf

DO SOFT MIST INHALERS HOLD THE KEY TO FASTER INHALATION DRUG DEVELOPMENT?

Wilbur de Kruijf and Bernhard Müllinger discuss the the market requirements for new inhalation options and the benefits of soft mist inhalers.

PULMONARY

Proveris Scientific

Technology Showcase: Testing Solutions for pMDI Drug Development

Proveris Scientific showcases its complete suite of testing solutions for pMDI drug development, which include Proveris by Design, Ergo Studies, Vereo SFMDx Actuators, and a new Kinaero Cx pMDI Collection System.

EXPERT VIEW

Dr Justin Lacombe

USING QUALITY BY DESIGN TO OPTIMISE THE COMBINATION PRODUCT JOURNEY

Justin Lacombe and Julie D Suman explain how applying quality by design principles to combination products improves development efficiency, aligns with design controls, and maximises product safety and efficacy.

EXPERT VIEW

Dr Caterina Minelli

AN INVITATION TO PARTICIPATE IN STANDARDISATION OF PARTICLE MEASUREMENTS FOR PHARMACEUTICALS

Caterina Minelli discusses the importance of co-operation between metrology institutes and the pharmaceutical industry in the pursuit of improving analytical techniques and standards for the characterisation of particle attributes in drug development.

EXPERT VIEW

Daniel Lock

EVOLUTION OF NEBULISATION FOR DRUG DELIVERY TO THE LUNGS

Daniel Lock discusses the latest innovations in nebuliser technology for drug delivery to the lungs.

PULMONARY

Pietro Pirera

IMA Group

MANUFACTURING DPIs: AN ENGINEERING PERSPECTIVE

Pietro Pirera discusses the optimal process parameters for microdose dry power inhalers achieved by dosator technology.

EXPERT VIEW

Anita Solanki

CAPSULES FOR DRY POWDER INHALATION – A COMPLETE PRODUCT

Anita Solanki, Jnanadeva Bhat and Justin Kalafat discuss capsules for dry powder formulation and consider their potential as a dosage form for patients with respiratory conditions and systemic illnesses.

PULMONARY

Harry Peters

DFE Pharma

COLLABORATION AIMS TO ACCELERATE DEVELOPMENT PROCESS IN DPI FORMULATION

Harry Peters explains how the collaboration between DFE Pharma, Hosokawa Micron and Harro Höfliger can help manufacturers save time and money in the development process for dry powder inhalers, enabling them to tackle unmet needs and unleash the potential of the significant market opportunity presented by dry powder inhalers.

EXPERT VIEW

Tom Oakley

DRUG DELIVERY DEVICE TRENDS FOR 2022

Tom Oakley looks at some of the current trends in the drug delivery industry and projects some of the key factors that will influence drug delivery decision making in 2022.

CONNECTIVITY

Adam Shain

Aptar Pharma

TOWARDS A NEW STANDARD OF CARE WITH APTAR PHARMA’S DIGITAL HEALTH

Adam Shain discusses how Aptar is building on the progress made in connected drug delivery devices to help realise their full potential by developing an open, end-to-end platform that will enable healthcare stakeholders to take a holistic view of the full drug delivery journey.

CONNECTIVITY

Dr Carola Fuchs

PARI

eFLOW TECHNOLOGY NEBULISERS WITH DIGITAL THERAPY MANAGEMENT: THE PARI CONNECT ECO-SYSTEM

Carola Fuchs and Simon Buchner describe PARI’s new nebuliser and digital Connect eco-system and how it supports patients, directly and indirectly, through carefully considered device usability in combination with digital therapy management solutions.

PULMONARY

Deborah Norris

Cambridge Design Partnership

WAITING FOR THE OUTBREATH – WHAT CAN COVID-19 BIOAEROSOL RESEARCH TELL US ABOUT INHALABLE DRUG DELIVERY?

Deborah Norris, Mark Allen, Karl Hewson and Karla Sanchez, discuss how the covid-19 pandemic has spurred research in the pulmonary space, which suggests that a patient-tailored approach based on their individual lung characteristics, facilitated by advanced technology, could improve patient health outcomes and quality of life.

PULMONARY

Siamac Parker

Qualicaps

CHARACTERISING WALL THICKNESS OF QUALI-V^®-I CAPSULES & ITS EFFECT ON CAPSULE PUNCTURE BY A DPI PIN

Siamac Parker, Sion Coulman, Prof James Birchall alongside Susana Ecenarro and Mahmoud Farag, present a study that uses optical coherence tomography to characterise the wall thickness of capsules at the dome position and investigates the importance of controlling the dome thickness of hard-shell capsules to be used in a dry powder inhaler.

CONNECTIVITY

Andreas Meliniotis

Vectura

MAKING THE CONNECTION BETWEEN EFFICACY AND ENVIRONMENTAL SUSTAINABILITY

Andreas Meliniotis looks at the factors that should be considered when designing devices with a view to sustainable connectivity.

EXPERT VIEW

Jamie Clayton

POWDER CHARACTERISATION: A CRITICAL TOOL FOR THE EVOLUTION OF INHALED DRUG DELIVERY

Jamie Clayton, Joana Pinto and Sarah Zellnitz discuss the benefits of multi-faceted powder characterisation in dry powder inhalation formulations and how it can support efforts to achieve net zero emissions.

PULMONARY

Raphaële Audibert

Nemera

LEVERAGING HUMAN FACTORS TO DEVELOP PATIENT-CENTRIC INHALERS

Raphaële Audibert, Mark Tunkel and Manuela Basso look at the role patient-centricity has to play in the development of inhalers to treat chronic respiratory diseases.

PHARMA VIEW

Dr Andrea Benassi

Chiesi

NUMERICAL SIMULATIONS FOR INHALATION PRODUCT DEVELOPMENT: ACHIEVEMENTS AND CURRENT LIMITATIONS

Andrea Benassi and Ciro Cottini discuss the current state of CFD and DEM computational modelling, how it is used to improve inhaler design and manufacturing, and what the current limitations of this technology are, as well as how those limitations may be overcome.

SUSTAINABILITY

Howard Burnett

Aptar Pharma

TOWARDS A MORE SUSTAINABLE FUTURE WITH pMDI SOLUTIONS

Howard Burnett, Chris Baron and Jay Bhogaita summarise the findings of a recent forum that looked at the development of more sustainable pressurised metered dose inhalers.

PULMONARY

Edgar Hernan Cuevas Brun

HCmed Innovations

DELIVERING SUSPENSIONS WITH MESH TECHNOLOGY

Edgar Hernan Cuevas Brun and Yuan-Ming Hsu discuss the performance of mesh nebulisers for the delivery of suspensions in inhalation therapy.

ROUNDTABLE

Frédérique Bordes-Picard

Lonza

ROUNDTABLE: CAPSULE-BASED DRY POWDER INHALERS

Frédérique Bordes-Picard of Lonza, Marco Franza of Berry, Mirjam Kobler of Meggle, and Marco Laackmann of Harro Höfliger, discuss the accelerating development potential of capsule-based dry powder inhalers (DPIs) and the potential of these effective and efficient drug delivery devices in the modern drug delivery market.

PULMONARY

Bas van Driel

DFE Pharma

TRANSFORMING DRUG DELIVERY WITH SYNERGISTIC WORKING

Bas van Driel discusses how expert collaborations can help develop a knowledge base to transform drug delivery and manufacturing. He shares how recent collaborative research projects involving lactose-based dry powder inhalation formulations, with and without magnesium stearate and lactose as an excipient in 3D tablet printing, have done just that.

SUSTAINABILITY

Julien Storz

Aptar Pharma

SUCCESSFULLY BALANCING THE NEEDS OF THE PLANET WITH THE NEEDS OF THE PATIENT

Christophe Marie, Taylor Price and Julien Storz chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.

SUSTAINABILITY

Louise Righton

Kindeva Drug Delivery

SIX INHALER SUSTAINABILITY MYTHS – AND WHY THEY MUST BE BUSTED

Louise Righton busts six sustainability myths about inhalers.

SUSTAINABILITY

Jacqueline Green

H&T Presspart

PLASMA TECHNOLOGY – THE FUTURE OF RESPIRATORY DEVICES

Jacqueline Green discusses how H&T Presspart’s plasma treatment process can provide a future-proof and sustainable solution for some of the issues associated with suspension formulations in the respiratory device industry.

CONNECTIVITY

Marcus Jarman-Smith

Victrex

CONNECTED DEVICES CHALLENGE: HOW TO DEVELOP CONCEPT DEVICES WITH PEEK POLYMERS

Marcus Jarman-Smith, Adam Salmen, John Devine, Ernst Hupkes and Dennis Freie discuss the value of PEEK, a high-performance polymer, in drug delivery device design, using two concept devices – an on-body patch pump and vaporiser inhaler.

CONNECTIVITY

Christina Philpott

Recipe Design

MEANING-CENTRED PRODUCT DEVELOPMENT: THE KEY TO SUCCESSFUL CONNECTED DISEASE MANAGEMENT

Christina Philpott, Miles Hawley and Natasha French, discuss the future of connected disease management and the potential benefits for asthma treatment.

CONNECTIVITY

Adam Shain

Aptar Pharma

PUTTING THEIR HEALTH IN THEIR HANDS: ENHANCING RESPIRATORY PATIENT OUTCOMES THROUGH DIGITAL THERAPEUTICS

Adam Shain discusses the role digital therapeutics play in respiratory patient outcomes and looks at the potential for expansion into other therapy areas.

CONNECTIVITY

Dr Young Kim

Celanese

SPECIALTY LCP COMPOUNDS FOR ELECTRONICS INTEGRATION IN CONNECTED MEDICAL DEVICES

Young Kim, Don DeMello and Philip Wilson, discuss the benefits of recent advances in liquid crystal polymer for connected medical devices.

RESPIRATORY

Harry Peters

DFE Pharma

PRACTICAL INSIGHTS INTO LACTOSE-BASED DPI FORMULATIONS, WITH & WITHOUT MAGNESIUM STEARATE

Partners DFE Pharma, Hosokawa Micron and Harro Höfliger describe their unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate, whose findings will give generic players a head-start in the development process so that they can tap into this rapidly growing market. The three companies announce that they will be presenting the key insights from their research to interested parties during a joint webinar on the June 30th, 2020.